Hoffmann-La Roche: Pricing the Zelboraf Melanoma Treatment for Canada Case Solution
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
PUBLICATION DATE: September 12, 2016
The Canadian brand name supervisor of Zelboraf had to choose how to price and present Zelboraf in the Canadian market. Hoffmann-La Roche (Roche) started establishing Zelboraf in 2005. It was likewise uncertain whether Dabrafenib's Canadian market launch would impact the possibility that Zelboraf got on the authorized drug list to protect federal government repayment. Roche had to set a rate that made sure success, however did not jeopardize Zelboraf's competitive position.
Related Case Solutions & Analyses:
Mabel’s Labels: Leading in a Results-Only Work Environment
Recruiting Faster: (B) Change Management at SDL
Mahindra Aerospace: Looking Ahead
Note on Application of Game Theory in Business
Jim Lander at Thamesford Logistics
Adam Root, MD (A)
Building the Virtuous Circle of Trust
Hydrofruit, Inc.: Ripe for Harvest or Rotten Tomato?
América Móvil: Building a Wireless Leader in Latin América
Robert Jones and the Eastbourne NHS Orthotics Clinic: Make or Buy?
